Growth of $23 billion by the year 2021 is anticipated in the global cholesterol-lowering drugs market, according to a new report from business intelligence provider, Visiongain.
cholesterol
The 181-page report provides analysis and insight into the global cholesterol-lowering drugs market, including revenue forecasts from 2017–2027, which are broken into four main segments: Statins and fixed-dose combinations; cholesterol absorption inhibitors, ion exchange resins, fibrates; PCSK9 inhibitors; and novel cholesterol-lowering drugs.